Colorectal cancer (CRC) is one of the most prevalent and deadly cancers worldwide.
Despite recent improvements in treatment and prevention, most of the current therapeutic …

Highlights•The epidermal growth factor (EGFR) is a therapeutic option for patients with all
RAS WT metastatic colorectal cancer (mCRC).•A better knowledge of the mechanism of …

Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …

Importance Rechallenge therapy with anti–epidermal growth factor receptor (EGFR) drugs
has been suggested in patients with chemo-refractoryRASwild-type (WT) metastatic …

Importance The available evidence regarding anti–epidermal growth factor receptor (EGFR)
inhibitor rechallenge in patients with refractory circulating tumor DNA (ctDNA) …

The most commonly mutated isoform of RAS among all cancer subtypes is KRAS. In this
review, we focus on the special role of KRAS mutations in colorectal cancer (CRC), aiming …

In the evolving molecular treatment landscape of metastatic colorectal cancer (mCRC), the
identification of druggable alterations is pivotal to achieve the best therapeutic opportunity …

Trastuzumab, a monoclonal antibody to human epidermal growth factor receptor 2 (HER2),
has improved survival in patients with HER2-positive advanced gastric or gastroesophageal …

Colorectal cancer (CRC) is the second most lethal cancer worldwide and the prognosis of
metastatic CRC (mCRC) remains poor. Recent advancements in translational research have …